CTAS vs TSHA · P/E 51, rev $11.26B vs $640.7M cap
Cintas Corporation (CTAS) versus Taysha Gene Therapies Inc (TSHA) — a side-by-side from cached financials, not a winner call.
Cintas Corporation (CTAS) is a specialty business services company listed on US.
Taysha Gene Therapies Inc (TSHA) is a biotechnology company listed on US.
Latest reported CTAS revenue for 2026-05-31 was $11.26B. Net income was $2.00B. Revenue was up 8.9% from 2025-05-31 to 2026-05-31. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
Latest reported TSHA revenue for 2026-06-30 was $0. Net income was -$89.0M. TSHA currently screens at market cap $640.7M.
CTAS currently screens at market cap $89.01B and trailing P/E 51.3. TSHA currently screens at market cap $640.7M.
Not investment advice. Open the CTAS and TSHA stock pages for the full models.
Not investment advice.